Gsk Share Discussion Threads

[montyhedge] 07/3/2018 09:16

Dow futures not looking good, get ready to batten down the hatches.

[nico9] 07/3/2018 08:58

btw I have read the Intro on the other BB which is interesting on its own especially future Dividends bit

[nico9] 07/3/2018 08:51

reading recent posts. There is talk about a Bid!!! and Pfizer name is also mentioned. Can anyone give a brief summary of Why there is talk of a Bid without me having to trawl back through historic posts etc
Thanks N

[nico9] 07/3/2018 08:31

thanks mate

[woodhawk] 07/3/2018 08:29

Next ex-d is 10th May for 19p.

[nico9] 07/3/2018 08:20

sorry to ask. anyone know the ex dividend date please? TIA

[abdullla] 07/3/2018 08:05

Lost every penny it gained yesterday,lucky day traders !

[juju44] 06/3/2018 17:06

Yep , gaps are pigs . If you put Wall St trading and London trading together , then the gap is now closed . Wishful thinking maybe. We will see

[abdullla] 06/3/2018 16:16

Lost nearly 20p from the highs of today!

[tradermichael] 06/3/2018 16:13

GlaxoSmithKline PLC said Tuesday that new clinical data from a phase 3 trial has demonstrated high efficacy of Fluarix Tetra, an influenza vaccine for young children.
GSK said that Fluarix Tetra prevented influenza types A and B--acute, highly contagious, respiratory diseases caused by influenza viruses which are mainly spread through respiratory droplets.

The company said Fluarix Tetra demonstrated 63.2% vaccine efficacy against laboratory-confirmed moderate-to-severe influenza, and efficacy of 49.8% against influenza of any severity in children aged six months to 35 months.

In culture-confirmed influenza, Fluarix Tetra demonstrated vaccine efficacy of 77.6% in moderate-to-severe influenza, and efficacy of 60.1% against influenza of any severity, GSK said.

[montyhedge] 06/3/2018 15:57

1225p if we win Pfizer consumer division bid.

[jrphoenixw2] 06/3/2018 15:44

Agreed gaps, perhaps esp higher, hold a kind of magnetic attraction, but by no means do they always fill.
As things are at time of writing:
Mon close 1308.80
Tue open 1320.40
Right now 1319.60
...so we're shaving the top off the gap. Depends on mood going into the close IME...

[juju44] 06/3/2018 13:59

Looks like a collapse back to fill the gap up . No surprise

[fangorn2] 06/3/2018 13:44

"Gilead's HIV med Biktarvy on par with Viiv's Triumeq in late stage study"

Patients receiving Biktarvy experienced 50% less drug-related adverse events (AEs) (8% vs. 16%) than the Triumeq group (p=0.006). Most were mild or moderate. The greater number of Triumeq-related AEs was driven primarily by a higher rate of GI distress (nausea, diarrhea, flatulence) and neuropsychiatric events (abnormal dreams, insomnia).

[montyhedge] 06/3/2018 13:44

Lol yes if we don't win Pfizer bid.

[woodhawk] 06/3/2018 13:42

Anod there'll be another 19p along shortly, Monty!

[montyhedge] 06/3/2018 10:26

Add the 23p we are going to get ex div now, 1355p not bad chaps.

[bluemango] 06/3/2018 09:38

"Parma's doing well"

Yep, Serrano and Prosciutto also. ;o)

[ny boy] 06/3/2018 09:33

Parma’s doing well, bought (SHP) on the recent dip, hopefully not long before the share price starts a good run north, quarterly divi is attractive of course 6% per annum or there abouts.

If (IMM)delivers transformational phase 3 Lupuzor results, due in a few weeks, I will add another £20-50k here.

[tradermichael] 06/3/2018 09:09

GlaxoSmithKline PLC said on Monday that its majority-owned ViiV Healthcare joint venture has reported positive interim results from a study of dolutegravir, a treatment for adults with both HIV and tuberculosis.

GSK said the ViiV phase IIIb study of dolutegravir showed the treatment was effective and well-tolerated in patients already receiving rifampin medication for tuberculosis.

[montyhedge] 06/3/2018 07:42

Of course 50/50 whether GSK win the bid. Looked at RB I just don't think their shareholders would be happy.Just have to wait and see.

[romeike] 05/3/2018 21:26

Monty your gut feeling turned 180 degrees from what you said in a recent post - do we take from that that you have indigestion!??

The issue impacting the share price is not so much will they buy it or won't they buy it, given the massive fall in share price already suffered it's likely a recovery would be most helped by the removal of uncertainty. The share price ought to go up either way, but I think a stronger recovery will occur if GSK opt not to buy.

[rlivsey] 05/3/2018 19:40

Bounced off the support nicely

[dr biotech] 05/3/2018 17:35

It would depend on the trial endpoint. Of course what this is will depend on what is being treated - this would be different. For something chronic, say IBS it will be are the symptoms improved after say 6 months, for cancer it may mean event free survival etc. What’s the drug/company?

[fangorn2] 05/3/2018 16:56

Glaxo's Nucala shows treatment benefit in asthma patients uncontrolled with Xolair